CTXR Citius Pharmaceuticals, Inc. Stock Quote

CTXR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	9.78%	Shs Outstand	134.70M	Perf Week	-2.73%
Market Cap	223.87M	Forward P/E	5.74	EPS next Y	0.31	Insider Trans	0.00%	Shs Float	68.11M	Perf Month	-6.81%
Income	-21.40M	PEG	-	EPS next Q	-0.07	Inst Own	7.00%	Short Float	10.71%	Perf Quarter	64.81%
Sales	-	P/S	-	EPS this Y	42.00%	Inst Trans	19.07%	Short Ratio	0.50	Perf Half Y	69.52%
Book/sh	0.45	P/B	3.96	EPS next Y	191.20%	ROA	-59.40%	Target Price	-	Perf Year	173.85%
Cash/sh	0.03	P/C	52.06	EPS next 5Y	-	ROE	-77.70%	52W Range	0.63 - 2.90	Perf YTD	74.51%
Dividend	-	P/FCF	-	EPS past 5Y	20.00%	ROI	-	52W High	-38.62%	Beta	1.53
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	-	Gross Margin	-	52W Low	182.54%	ATR	0.14
Employees	10	Current Ratio	1.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.56	Volatility	6.16% 7.14%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	1.00%	Profit Margin	-	Rel Volume	0.33	Prev Close	1.83
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	14.67M	Price	1.78
Recom	2.00	SMA20	-5.80%	SMA50	-0.00%	SMA200	40.17%	Volume	4,776,230	Change	-2.73%

Mar-23-21 09:00AM	Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25 PR Newswire
Mar-04-21 10:11AM	Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10 PR Newswire -7.81%
Feb-19-21 04:47PM	Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire +32.05%
11:34AM	CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge InvestorPlace
Feb-17-21 12:28AM	Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire -11.83%
Feb-16-21 09:15AM	Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021 PR Newswire +24.26%
Feb-08-21 08:35AM	Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing PR Newswire
Feb-04-21 10:16AM	Citius Pharmaceuticals Is Addressing Several Unmet Needs In The Medical Field Benzinga -8.33%
Feb-02-21 08:00AM	Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4 PR Newswire +10.26%
Jan-28-21 08:35AM	Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th PR Newswire
Jan-27-21 01:00PM	Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market PR Newswire
Jan-25-21 07:00AM	Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market PR Newswire
Jan-06-21 09:00AM	Citius Pharmaceuticals to Present Update on Proprietary Product Candidates at Two Virtual Conferences in January PR Newswire
Dec-18-20 12:57AM	Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Invest In Growth? Simply Wall St.
Dec-15-20 09:40AM	Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19 PR Newswire
Dec-09-20 09:40AM	Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap PR Newswire
Dec-08-20 09:15AM	Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS") PR Newswire
Dec-03-20 03:30PM	Citius Pharmaceuticals to Present Corporate Update at Benzinga Global Small Cap Conference on December 8 PR Newswire +11.88%
Nov-30-20 09:15AM	Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components PR Newswire
Nov-10-20 09:30AM	Citius Pharmaceuticals to Present at Virtual Fall Investor Summit PR Newswire
Nov-09-20 09:30AM	Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference PR Newswire
Oct-27-20 09:00AM	Citius Pharmaceuticals Issues October 2020 Letter to Shareholders PR Newswire
Oct-13-20 07:30AM	Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions PR Newswire
Oct-07-20 07:00AM	Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) PR Newswire +6.93%
Sep-30-20 09:45AM	Citius's Mino-Lok trial sites resupplied with registration batch product PR Newswire
Sep-29-20 10:17AM	Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial PR Newswire
Sep-22-20 08:15AM	Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok® PR Newswire
Sep-15-20 10:17AM	Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance PR Newswire +6.88%
Sep-08-20 10:00AM	Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference PR Newswire
Sep-01-20 04:34PM	LD Micro: 360 Companies--Set to Present this Week. ACCESSWIRE
Aug-27-20 09:00AM	Citius Pharmaceuticals to Present at the LD 500 Virtual Conference PR Newswire
Aug-26-20 10:00AM	Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap PR Newswire +7.46%
Aug-13-20 09:45AM	Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo PR Newswire
Aug-10-20 03:18PM	Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares PR Newswire
Aug-05-20 05:32PM	Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering PR Newswire
09:00AM	LD Micro - Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE
Aug-04-20 08:17AM	Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult PR Newswire
Jul-22-20 10:30AM	Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19 PR Newswire
Jul-20-20 02:00PM	Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event PR Newswire
Jul-14-20 08:47AM	Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President PR Newswire
Jul-13-20 08:15AM	Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements PR Newswire -8.21%
Jun-30-20 08:54AM	Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1% Zacks -22.07%
Jun-29-20 09:07AM	Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides PR Newswire +5.07%
08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire
Jun-26-20 09:00AM	Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19 PR Newswire +27.78%
Jun-23-20 08:49AM	Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020 GlobeNewswire
Jun-22-20 01:17PM	Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum PR Newswire
Jun-02-20 09:30AM	Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy PR Newswire
May-26-20 08:15AM	Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok® PR Newswire
May-18-20 02:30PM	Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire
May-15-20 06:49AM	Should You Be Concerned About Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Historical Volatility? Simply Wall St.
May-14-20 09:00AM	Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire -25.23%
May-13-20 08:15AM	Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting PR Newswire +5.71%
May-12-20 08:00AM	Citius Pharmaceuticals Issues May 2020 Shareholder Letter PR Newswire +9.38%
Apr-27-20 09:30AM	Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 PR Newswire +6.17%
Apr-01-20 08:07AM	Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 PR Newswire +36.64%
Mar-26-20 09:06AM	Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris PR Newswire +6.25%
Mar-18-20 09:46AM	Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit PR Newswire -5.41%
Mar-16-20 06:22AM	Here's Why We Worry About Citius Pharmaceuticals's (NASDAQ:CTXR) Cash Burn Situation Simply Wall St. -7.41%
Mar-03-20 04:45PM	Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City ACCESSWIRE
Feb-26-20 08:00AM	Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference PR Newswire
Feb-25-20 08:00AM	Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok® PR Newswire
Feb-10-20 08:28AM	Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference PR Newswire
Feb-04-20 08:00AM	Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial PR Newswire
Feb-03-20 08:00AM	Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements PR Newswire -6.78%
Jan-27-20 08:00AM	Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses Newsfile -9.60%
Dec-19-19 08:00AM	Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial PR Newswire
Dec-04-19 08:00AM	Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event PR Newswire
Nov-08-19 08:00AM	Citius Pharmaceuticals Issues Corporate Update PR Newswire
Oct-24-19 08:00AM	Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference PR Newswire -5.81%
Oct-15-19 08:00AM	MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE
08:00AM	MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019 ACCESSWIRE
08:00AM	Citius Pharmaceuticals to Present at the MicroCap Rodeo PR Newswire
Oct-07-19 08:30AM	Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial PR Newswire +6.15%
Oct-03-19 07:00AM	Citius Provides Update on Activities From IDWeek 2019 PR Newswire
Sep-28-19 07:52AM	Insider Buying: The Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Executive Chairman & Secretary Just Bought US$2.0m Worth Of Shares Simply Wall St.
Sep-27-19 11:28AM	Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market PR Newswire -5.57%
Sep-25-19 07:00AM	Citius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market PR Newswire
Sep-04-19 06:55AM	Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study PR Newswire +7.62%
Aug-29-19 08:00AM	Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith. PR Newswire
Jul-30-19 08:00AM	Citius Provides Developmental Plans for Mino-Wrap PR Newswire +6.98%
Jul-24-19 03:38PM	Have Insiders Been Buying Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Shares? Simply Wall St.
May-24-19 08:53AM	Could Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Investor Composition Influence The Stock Price? Simply Wall St.
May-13-19 08:47AM	Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris PR Newswire
May-01-19 08:00AM	Citius Pharmaceuticals to Present at the ThinkEquity Conference PR Newswire
Apr-30-19 09:45AM	Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy PR Newswire
Apr-23-19 08:30AM	MicroCap Review Magazine Spring 2019 Issue Now Available ACCESSWIRE
Apr-05-19 07:15PM	Citius Pharmaceuticals Inc (CTXR) President and CEO Myron Z Holubiak Bought $200,648 of Shares GuruFocus.com
Apr-04-19 08:30AM	Citius Pharmaceuticals Successfully Raises $5.3 Million PR Newswire -8.34%
Apr-01-19 09:00AM	Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market PR Newswire -6.34%
Mar-12-19 08:45AM	LD Micro Virtual Conference Is Live, March 12th and 13th ACCESSWIRE +8.15%
Mar-11-19 02:23PM	Imagine Owning Citius Pharmaceuticals (NASDAQ:CTXR) And Taking A 97% Loss Square On The Chin Simply Wall St. +8.00%
Feb-27-19 12:30PM	Four Tech Stocks Looking To Test February Highs ACCESSWIRE +5.51%
Jan-25-19 08:00AM	Citius Pharmaceuticals to Present at NobleCon15 Investor Conference PR Newswire
Jan-08-19 09:00AM	Citius Licenses Mino-Wrap From MD Anderson Cancer Center PR Newswire
Jan-04-19 10:45AM	Citius Pharmaceuticals to Present at Biotech Showcase Investor Conference PR Newswire
Dec-19-18 09:45AM	Citius Pharmaceuticals Provides Updates on Mino-Lok® and CITI-002 PR Newswire
Dec-10-18 08:35AM	Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing PR Newswire -5.22%
Dec-04-18 08:35AM	Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th PR Newswire
Nov-30-18 08:00AM	Citius Pharmaceuticals to Present at the 11th Annual LD Micro Main Event PR Newswire

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience